Moving off the critical path: Streamlining strategies for drug substance synthesis and manufacturing
Richard Castledine talks to Pharmaceutical Technology about moving off the critical path and streamlining strategies for drug substance synthesis and manufacturing
Helen Baker Featured in Drug Development & Delivery: "Outsourcing Formulation Development & Manufacturing" Article
Helen Baker, Director, Pharmaceutical Sciences at Quotient Sciences has recently been featured in Drug Development & Delivery's Special Feature: "Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product"
Pharma's Almanac - Mark Egerton - Q: What’s the key to being a leader in the industry?
Mark Egerton, CEO of Quotient Sciences was recently asked to contribute to a piece with Pharma's Almanac, entitled 'What’s the key to being a leader in the industry?'
DCAT Value Chain Insights - CDMO Roundtable: Managing Orphan Drug Projects
Roundtable Interview with Paul Quigley, Principal Research Fellow, Drug Substance,& John McDermott, Executive Drug Development Consultant. Low-volume drugs, such as orphan drugs, present challenges in achieving favorable production economics and in managing the projects themselves. A roundtable of CDMOs provides perspectives on those challenges and best practices to resolve them.
Mark Egerton, CEO of Quotient Sciences - 'Keeping Up With Demands: CDMOs diversify their capabilities to meet their clients’ complex requirements', featured in Global Business Reports
Mark Egerton, CEO of Quotient Sciences, has been featured in and article in Global Business Reports: "Keeping Up With Demands: CDMOs diversify their capabilities to meet their clients’ complex requirements."
Nand Singh Contributes to Recent Study Article, "Absorption, metabolism and excretion of opicapone in human healthy volunteers"
Nand Singh, Medical Director at Quotient Sciences, contributes to a recent bial study paper in the British Journal of Clinical Pharmacology. This paper documents the study - absorption, metabolism and excretion of opicapone (2,5-dichloro-3-(5-[3,4-dihydroxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide), a selective catechol-O-methyltransferase inhibitor investigations.